CN Patent

CN115175685B — 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸

Assigned to Eperik Co · Expires 2024-12-13 · 1y expired

What this patent protects

提供了组合物，所述组合物包含靶向血管生成素样4(ANGPTL4)的寡核苷酸。所述寡核苷酸可以包括小干扰RNA(siRNA)或反义寡核苷酸(ASO)。本文还提供了通过向有需要的对象提供靶向ANGPTL4的寡核苷酸来治疗代谢或心血管病症的方法。

USPTO Abstract

提供了组合物，所述组合物包含靶向血管生成素样4(ANGPTL4)的寡核苷酸。所述寡核苷酸可以包括小干扰RNA(siRNA)或反义寡核苷酸(ASO)。本文还提供了通过向有需要的对象提供靶向ANGPTL4的寡核苷酸来治疗代谢或心血管病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN115175685B
Jurisdiction
CN
Classification
—
Expires
2024-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Eperik Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.